Pulmatrix Announces Closing of $40 Million Registered Direct Offering
News provided by
Share this article
Share this article
LEXINGTON, Mass., Feb. 16, 2021 /PRNewswire/ Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it has closed its previously announced registered direct offering with certain healthcare-focused institutional investors for the sale of 20,000,000 shares of its common stock for gross proceeds of $40,000,000, prior to deducting placement agent s fees and other offering expenses.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences
News provided by
Share this article
Share this article
WESTBROOK, Maine, Feb. 16, 2021 /PRNewswire/ IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, will participate in two upcoming conferences:
Thursday, February 25, 11:45 am EST – Jay Mazelsky, President and Chief Executive Officer, and Brian McKeon, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the BofA Securities Animal Health Summit.
Monday, March 1, 9:10 am EST – Jay Mazelsky, President and Chief Executive Officer, will participate in a virtual fireside chat at the 42
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Global Gene Therapy Partnering Agreements 2010-2020 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.
Comprehensive access to 530 actual gene therapy deals entered into by the world s biopharma companies, together with real world clause examples.
The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapy technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Share this article
ORLANDO, Fla., Feb. 16, 2021 /PRNewswire/
IMA Medical Group, a leading independent provider of high-quality primary care physician services in Central Florida, has earned the Patient-Centered Medical Home (PCMH) recognition by the National Committee for Quality Assurance (NCQA).
The NCQA Patient-Centered Medical Home program reflects the input of the American College of Physicians (ACP), American Academy of Family Physicians (AAFP), American Academy of Pediatrics (AAP) and American Osteopathic Association (AOA) and others.
It was developed to assess whether clinician practices are functioning as medical homes and recognize them for these efforts.
The NCQA Patient-Centered Medical Home standards emphasize the use of systematic, patient-centered, coordinated care that supports access, communication and patient involvement.
Share this article
Share this article
DALLAS, Feb. 16, 2021 /PRNewswire/ Care Continuity Inc., a leader in patient navigation and care transitions, today announced that it has appointed to its board of directors Dr. Anthony Coletta, former executive chairman of Tandigm Health, a leading population health services organization. We are pleased to welcome Dr. Coletta, who joins us at an exciting time as we continue to drive our strategy forward to improve network integrity, the patient experience, and clinical outcomes with fully connected care delivery and seamless care transitions, said Andrew Thorby, founder and CEO, Care Continuity. The addition of Dr. Coletta complements our board of directors, and we are confident he will provide valuable perspectives as we continue to enhance our suite of solutions and services in the years ahead. We look forward to his contributions and are excited he chose Care Continuity.